Quantinuum's IPO Implies Triple-Digit Revenue Growth For Five Years. Its Signed-Order Backlog Is $77 Million.

On 3 June 2026, Quantinuum set the price of its initial public offering (IPO), the first sale of its shares to the public, at $60 a share. That was the top of a price range the company had pushed higher several times, after it also increased the size of the deal to 28 million Class A sharesClass A sharesThe type of stock sold to the public in this IPO; companies sometimes create different share classes that carry different voting or ownership rights.. The sale brought in $1.68 billion before fees. The next morning the stock opened at $68 on the NasdaqNasdaqA major U.S. stock exchange, a marketplace where shares of public companies are bought and sold. exchange under the ticker symbolticker symbolThe short code, here QNT, used to identify a company's stock when trading it. QNT, about 13 percent above the $60 offer price, briefly touched $71.35, then gave back the gain and closed up just 0.6 percent, essentially flat, on its first day of trading.

Several news outlets read that flat close as a sign of caution in an otherwise overheated quantum sector. CNBC noted the muted debut against a backdrop where quantum stocks often rise and fall together based on mood rather than results, and contrasted it with AI-chipmaker Cerebras, whose shares jumped nearly 70 percent on their first day a few weeks earlier. The more lasting fact is the price itself. At $60, once you count the HoneywellHoneywellThe large industrial conglomerate that backs Quantinuum and remains its dominant shareholder after the IPO.-controlled stakes and other insider holdings that can later be swapped into ordinary public shares, Quantinuum is worth about $15.66 billion in total. Its auditedauditedChecked and confirmed by an independent accounting firm, which makes the figures more trustworthy. revenue (sales confirmed by an outside accountant) for the year ended 31 December 2025 was $30.9 million. That works out to a price-to-sales ratio of roughly 507 times, meaning investors are paying about $507 for every $1 of last year's sales, while the company actually lost $192.6 million that year.

This is the first big quantum-computing company to go public through a conventional, bank-managed IPO rather than by merging into a shell company set up purely to take a business public (a SPAC, or special-purpose acquisition company), the route IonQ, Rigetti and D-Wave all took in 2021 and 2022. That makes it an unusually clean test of one question: will public investors fund quantum computingquantum computingAn experimental kind of computing that uses the strange rules of quantum physics to try to solve certain problems far faster than ordinary computers. based on real sales, or on the promise of sales to come? Part of the answer is already baked into the price, and we can examine it with simple arithmetic instead of just arguing about it.

The easy take is already written: 507 times sales is a bubble, end of story. That is not so much wrong as incomplete, because it stops at last year's number. A fast-growing company is supposed to grow into a high price over time. The sharper question is not whether 507 times sales is high, which it obviously is, but what future the price actually requires, under assumptions we state out loud, and whether anything in the company's own filing supports that future.

So we ran the calculation in reverse. This needs one assumption that does a lot of the heavy lifting, and we want to flag it rather than hide it: the price-to-sales ratio the market will eventually settle on once Quantinuum's growth slows to normal (we call this the terminal multipleterminal multipleThe price-to-sales ratio assumed to apply once a fast-growing company's growth eventually settles down to a normal pace.). Nobody can know that number today, so we pick a range and test how sensitive the answer is to it. Mature technology companies that are still growing typically trade at a price-to-sales ratio in the high single digits to mid teens based on expected future sales, so we use a band of 8 to 15 times, with 10 times as our base case, and treat the result as a what-if scenario rather than a prediction. If Quantinuum is to be worth its IPO valuation at a 10-times forward sales ratio by its 2030 financial year, we can solve for the revenue it would need to reach, and from there the steady annual growth rate (the compound annual growth rate, or CAGR) it would have to sustain. The other inputs are public: about 260.97 million fully diluted sharesfully diluted sharesThe total number of shares that would exist if every stake that can be converted into ordinary shares were converted. (all shares that would exist if every convertible stake were turned into ordinary shares) times $60 is roughly $15.66 billion of equity valueequity valueThe total value of all the company's ownership stakes added together.; the 2025 revenue starting point is $30.9 million; the time horizon is five years.

The terminal multiple is an assumption, not a fact we can measure. We state the range, test how much it matters, and let the reader see how far the headline number moves.

Under the 10-times base case, to be worth its $15.66 billion valuation by the 2030 financial year while handing its IPO buyers exactly zero profit, Quantinuum would have to grow recognized revenue from $30.9 million to about $1.57 billion. That is a compound annual growth rate of roughly 119 percent, sustained without a single stumble for five years in a row. (Growing 119 percent a year means sales would have to more than double every year for five straight years.)

This conclusion is not one shaky estimate; it is a range that holds up under any reasonable terminal multiplemultipleA shorthand for a valuation ratio like price-to-sales; a high multiple means investors are paying a lot relative to current results.. Allow a richer 15-times forward ratio and the required growth eases to about 102 percent a year. Use a more conservative 8 times and it rises to about 129 percent; at 5 times, to about 152 percent. All of those figures assume the IPO buyer earns nothing at all. To also give those buyers a normal stock-market return of 10 to 15 percent a year, the required growth at a 10-times terminal multiple climbs to roughly 141 to 152 percent. So the honest statement is a range, not a single number: to justify the price, Quantinuum needs sales growing somewhere between about 102 and 152 percent a year for five straight years. No version of the math escapes triple-digit annual growth, which is the robust finding here; the exact figure depends on the assumptions we have spelled out.

Now set that requirement against the one forward-looking, contracted figure the company discloses. As of 31 March 2026, Quantinuum's remaining performance obligations, accounting jargon for revenue it has signed contracts to earn but has not yet delivered or booked, totaled $76.8 million. This is, in effect, its backlog of signed orders. The filing says about 35 percent is expected to turn into revenue within twelve months. Spreading the rest over the next few years implies very roughly $20 million to $27 million of contracted revenue a year. Two cautions matter here. First, the backlog is a one-time pile of signed contracts, while the implied $1.57 billion is a single year's flow of 2030 revenue; the fair comparison spreads the backlog out into a yearly figure before placing it next to a year of sales. Second, a backlog can grow as new contracts are signed, so this is a snapshot, not a fixed fate. With those caveats, an annualized backlog of around $20 million sits far below the roughly $1.57 billion the base case requires for 2030.

What about the pace of new deals coming in? Quantinuum's bookings, the total dollar value of new contracts signed during a period, were $1.3 million in the first quarter of 2026, down from $1.9 million a year earlier. We resist reading a trend into that. The company signed $79.3 million of bookings across all of 2025, so a single $1.3 million quarter cannot prove the business is weakening; analysts and the company itself describe the business as lumpy, meaning it leans on a handful of large deals with big institutions and governments rather than steady, repeating revenue. The cleaner reading is not that bookings are collapsing, but that they swing around so much that no single quarter tells you anything reliable, which is itself a problem for a price that needs a smooth, uninterrupted 119 percent climb.

Press coverage settled on a tidy line: roughly a $14 billion valuation, $31 million in revenue, more than 450 times sales. Two things are worth adding, and both cut against the company rather than for it.

First, that price-to-sales ratio is understated, not overstated. The $14 billion headline counts only the Class A shares sold in the IPO. But Quantinuum uses what is called an Up-C structureUp-C structureAn ownership setup that lets a company's original owners keep their stake in the underlying business and swap it into public shares over time, often for tax advantages., a setup that lets the original owners keep their stake in the underlying business and swap it into public stock later. Honeywell and other insiders hold these convertible units, and the filing shows that public Class A shareholders own only about 12 percent of the actual economic interesteconomic interestThe share of a company's actual profits and value that an owner is entitled to, regardless of how voting rights are split. in the company. Count the full ownership, the roughly 260.97 million fully diluted units the filing lists, and the company is worth about $15.66 billion, putting the ratio at roughly 507 times sales, not 450. The public is buying a thin slice of a more expensive whole.

Second, the revenue is concentrated in so few customers that any single-year sales figure is fragile. One outlet covering the filing reports, and the filing confirms, that a single research customer, the Japanese institute RIKENRIKENA large Japanese government-affiliated research institute that has been one of Quantinuum's biggest customers., accounted for about 60 percent of Quantinuum's revenue for full-year 2025 (and as much as 90 percent in the first quarter of 2025) but only about 7 percent of first-quarter 2026 revenue. That heavy reliance on a few customers is also why the quarter-to-quarter numbers swing so violently, as the next point shows.

It is tempting to point to Quantinuum's first-quarter 2026 revenue of $5.2 million, down from $19.1 million a year earlier, as proof the business is shrinking. That reading would be misleading without the cause the company discloses. The filing pins the drop mostly on the absence of upfront revenue from a one-off equipment deal a year earlier (a sales-type leasesales-type leaseAn accounting treatment for leasing out equipment that lets a company record a large chunk of the revenue upfront, at the start of the deal., an accounting treatment that lets a company book a chunk of revenue at the start). Revenue from selling specialized hardware fell from about $16.5 million in the year-ago quarter to essentially nothing. Because the year-earlier figure was inflated by that single transaction, the decline is mechanical, not a sign of falling demand. The honest point is sharper than the misleading one: a business whose quarterly revenue can swing nearly fourfold on a single deal is exactly the kind that is hard to justify at 507 times sales.

A single equipment deal swings quarterly revenue nearly fourfold. That lumpiness, not the direction of any one quarter, is what makes a 507-times multiple hard to justify.

There are at least two honest ways to read the same price, plus a third that complicates both. We state the optimistic case at its strongest.

The bull case (the optimistic view): triple-digit quantum growth is clearly real, so the wall of required growth can be climbed. The proof is rival IonQ. It grew revenue under standard U.S. accounting rules (known as GAAP) from $43.1 million in its 2024 financial year to $130.0 million in 2025, up 202 percent, then reported record first-quarter 2026 revenue of $64.7 million, up 755 percent from a year earlier, and raised its full-year 2026 sales forecast to $260 to $270 million. Its own backlog of signed orders reached $470 million as of 31 March 2026, up 554 percent year on year. The category can clearly ramp up fast, and judged on future, contract-backed sales, a high quantum multiple looks less absurd than last year's snapshot suggests.

The bear case (the skeptical view), which the same evidence supports more directly: the growth is real but spread unevenly, and Quantinuum is not where the signed orders are most visible. IonQ's $470 million backlog is roughly six times Quantinuum's $76.8 million in plain dollar terms, and IonQ's revenue is already about four times larger. Yet the fastest-growing, best-contracted name in the group carries a far lower price-to-sales ratio, about 109 to 115 times versus Quantinuum's 507. The bull case proves triple-digit quantum growth exists somewhere; it does not show that growth is locked in by contracts at Quantinuum today.

A third reading complicates the bear case, and is the fairest test we can apply. If we are going to hold Quantinuum's backlog against its valuation, we have to do the same for its rivals. IonQ's $470 million backlog is only about 1.8 times its own expected 2026 revenue of roughly $265 million, so even its order book covers well under two years of near-term sales, not the multi-year surge its valuation implies. Every company in this sector is priced beyond its order book; that is a feature of the whole category, not a quirk of Quantinuum. What sets Quantinuum apart is the size of the gap compared with the others: it carries both the highest price-to-sales ratio and, on the disclosed figures, the thinnest cushion of near-term signed orders. So the defensible claim is not that Quantinuum is uniquely unsupported, but that it sits at the worst extreme of a sector that is uniformly priced ahead of its contracts.

What would tip the balance toward the bull case is something specific and watchable: a sudden jump in Quantinuum's quarterly bookings and signed-order backlog in its first few reports as a public company, of the kind IonQ delivered when its backlog jumped 554 percent. What supports the bear case today is that the only forward-looking signals in the filing, a $76.8 million backlog and modest recent bookings, are small both against the requirement and against rivals.

The natural comparison is the group of quantum companies that went public around 2021, and it is useful precisely because of how it breaks down. IonQ, Rigetti and D-Wave all reached the public markets in 2021 and 2022 through SPAC mergers (the shell-company route described earlier) at lofty valuations. Then came the 2022 quantum winterquantum winterThe 2022 downturn when quantum-computing stocks fell sharply after their initial hype faded., a sharp downturn when these stocks crashed, before the link to the artificial-intelligence boom reignited the sector from late 2024 onward.

The part that matters for Quantinuum is that across that whole cycle, debut, crash and re-inflation, the group's price-to-sales ratios moved far more because share prices moved than because sales caught up. As of 22 May 2026, measured as market value divided by the past year's revenue, IonQ traded at roughly 109 times sales, Rigetti at roughly 836 times, and D-Wave at roughly 791 times. By mid-June, IonQ sat near 115 times at a market value of about $23 billion. The collapse and recovery in this group came overwhelmingly from the share price moving, not from revenue closing the gap. That is the key similarity: in this sector, the multiple has behaved largely like a mood gauge.

Where the comparison breaks, and not in Quantinuum's favor, is how each company went public. A SPAC debut sets a price through a negotiated merger that comes with pressure from investors cashing out and often a small pool of freely traded shares. Quantinuum, by contrast, was priced through a conventional, bank-managed IPO led by J.P. Morgan and Morgan Stanley, with real demand from large institutional investorsinstitutional investorsLarge professional investors such as pension funds, mutual funds, and asset managers, as opposed to individual retail buyers. and a flat, orderly first day. That makes the 507-times multiple a more considered judgment by the market than a SPAC price tag, and harder to wave away as a quirk of the structure. But the comparison also breaks in a way that helps Quantinuum, and we should say so: the 2021 and 2022 companies went public earlier in their commercial life, while Quantinuum arrives with a larger Honeywell-backed engineering operation and an established hardware business. So the comparison is directional, not exact; it tells us how this market prices quantum companies, not what Quantinuum's revenue will actually do.

A second comparison, this one inside Quantinuum's own history, sharpens the point. Honeywell's private valuations for Quantinuum climbed from about $5 billion in early 2024 toward $10 billion in 2025 and to roughly $15.7 billion at the June 2026 IPO. Revenue over a similar stretch moved from $23.0 million in the 2024 financial year to $30.9 million in 2025. The rising valuations are mostly a record of growing expectations, not of growing revenue.

The most exposed buyers are the IPO subscribers who paid $60 for about 12 percent of the company's economic interest, because the implied-growth math shows how much has to go right just for them to break even. Honeywell and the continuing unit holders, by contrast, are mostly marking up a stake they already owned rather than putting fresh cash in at this price, and they keep the bulk of the economic interest through the Up-C structure.

What would confirm the bull case is specific and near-term: in its first two or three quarters as a public company, Quantinuum would need its bookingsbookingsThe total dollar value of new customer contracts a company signs during a given period. and signed-order backlog to jump by roughly tenfold, toward the $400 million-plus backlog IonQ now reports, and its revenue to start a steady climb rather than bounce around on one-off hardware deals. The evidence to watch is the backlog and bookings disclosure in its first quarterly report to regulators (the 10-Q10-QThe quarterly financial report that public U.S. companies must file with securities regulators.), plus any large multi-year government or research contracts announced in the meantime.

What would confirm the bear case is the absence of that jump: a few more quarters of single-digit-million revenue swinging on individual deals, a backlog stuck in the tens of millions, and customer concentrationcustomer concentrationWhen a large share of a company's revenue comes from just one or a few customers, which is risky if one leaves. that stays heavy. If, by the time the post-IPO lockup expires (the period after an IPO when insiders are barred from selling) and insiders can begin swapping and selling their units, the order book still looks like today's, then the multiple would have to come down the way the 2021 and 2022 group's did, through the price falling, not through revenue rising to meet it.

This is an analysis of what the price implies about required growth, not a forecast of Quantinuum's revenue. We do not predict what the company will earn; we quantify what the price assumes under stated terminal-multiple scenarios and compare that with the contracted figures the company discloses. The single biggest source of uncertainty is the terminal multiple itself, which we assume rather than measure, which is why we report a range rather than one number. Peer multiples move daily and depend on which revenue figure is used and on whether the price tag is the public-share market value or the fully diluted value; we have dated each one and used market value divided by the past year's revenue throughout. Backlog and bookings are lumpylumpyDescribes revenue or orders that arrive in uneven bursts, often from a few big deals, rather than in a steady stream. in this sector, so single-quarter figures are weak signals on their own, a caution that applies equally to Quantinuum and to its peers.